Messina Kathryn M M, Woys Ann Marie
Pharmaceutical Development Department, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
Pharm Res. 2023 Feb;40(2):525-536. doi: 10.1007/s11095-022-03436-2. Epub 2022 Nov 15.
Developing stable high concentration monoclonal antibody (mAb) formulations is increasingly important to move toward subcutaneous (SC) administration for better patient experience. Challenges stemming from protein-protein interactions in these crowded solutions, such as colloidal instability, limit the feasibility of some formulations because of concerns of safety, product quality, and/or manufacturability. Herein, we report novel random heteropolymer excipients that improve the colloidal stability of a high concentration mAb formulation for SC administration.
A library of polymers was synthesized and screened by a high-throughput, absorbance-based assay. The lead polymers were selected and characterized for their ability to alter the precipitation kinetics of a mAb in physiologically relevant conditions using two model systems.
Biophysical testing via surface tension measurements, isothermal titration calorimetry (ITC), microscale thermophoresis (MST), and intrinsic fluorescence quenching indicated that the polymers delayed onset of mAb precipitation from a combination of surfactant behaviour and interactions with the protein to prevent protein-protein interactions leading to colloidal instability.
The random heteropolymers described are a new class of excipients that may enable development of SC mAb formulations previously inaccessible to patients.
开发稳定的高浓度单克隆抗体(mAb)制剂对于转向皮下(SC)给药以改善患者体验变得越来越重要。这些拥挤溶液中蛋白质 - 蛋白质相互作用所带来的挑战,如胶体不稳定性,由于对安全性、产品质量和/或可制造性的担忧,限制了某些制剂的可行性。在此,我们报告了新型无规杂聚物赋形剂,其可提高用于皮下给药的高浓度mAb制剂的胶体稳定性。
合成了一个聚合物文库,并通过基于吸光度的高通量测定法进行筛选。选择了先导聚合物,并使用两个模型系统对其在生理相关条件下改变mAb沉淀动力学的能力进行了表征。
通过表面张力测量、等温滴定量热法(ITC)、微量热泳动(MST)和固有荧光猝灭进行的生物物理测试表明,聚合物通过表面活性剂行为以及与蛋白质的相互作用的组合延迟了mAb沉淀的开始,以防止导致胶体不稳定性的蛋白质 - 蛋白质相互作用。
所描述的无规杂聚物是一类新型赋形剂,可能使患者能够使用以前无法获得的皮下mAb制剂。